Feb 26 (Reuters) – Eli Lilly on Thursday released new data from a head-to-head trial of its experimental weight-loss pill, orforglipron, and rival Novo Nordisk’s oral semaglutide in diabetes patients, giving a more detailed picture of the side effects.
(Reporting by Mariam Sunny in Bengaluru; Editing by Anil D’Silva)
Comments